Results 21 to 30 of about 12,086 (99)

Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review

ClinicoEconomics and Outcomes Research, 2020
Chakrapani Balijepalli,1 Lakshmi Gullapalli,1 Eric Druyts,1 Kevin Yan,1 Kamal Desai,1 Stephane Barakat,2 Jason Locklin2 1Pharmalytics Group, Vancouver, British Columbia, Canada; 2Alexion Pharmaceuticals, Vaughan, Ontario, CanadaCorrespondence: Chakrapani
Balijepalli C, Gullapalli L, Druyts E, Yan K, Desai K, Barakat S, Locklin J   +6 more
doaj  

Типы и методы проведения научного анализа исходов

Качественная клиническая практика, 2018
Клиническая ценность каждого лекарственного препарата определяется его эффективностью, переносимостью и безопасностью. В связи с появлением на фармацевтическом рынке большого количества препаратов у медицинских работников появилась возможность выбора ...

doaj  

Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis

ClinicoEconomics and Outcomes Research, 2021
Marco Bellone,1 Lorenzo Pradelli,1 Stefano Molica,2 Adele Emanuela De Francesco,3 Daniela Ghislieri,4 Emanuele Guardalben,5 Antonietta Caputo4 1Department of Health Economics and Outcome Research, AdRes Health Economics and Outcomes Research, Turin ...
Bellone M, Pradelli L, Molica S, De Francesco AE, Ghislieri D, Guardalben E, Caputo A   +6 more
doaj  

QALYs: The Basics

Качественная клиническая практика, 2018
.
M. C. Weinstein, George Torrance, Alistair Mcguire, I. A. Vilum, S. L. Plavinskii, D. Yu. Belousov   +5 more
doaj  

International experience in determining the cost-effectiveness thresholds

Фармакоэкономика, 2019
The article reviews international methodological guidelines, regulatory documents and existing approaches to the determination of the costeffectiveness threshold (CeT), also known as the willingness-to-pay threshold (WTP), the threshold value of the ...
T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky   +5 more
doaj   +1 more source

First-line nivolumab plus ipilimumab or chemotherapy chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis

Therapeutic Advances in Medical Oncology, 2022
Background: This study evaluated the cost-effectiveness of nivolumab plus chemotherapy (NC) or ipilimumab versus chemotherapy as a first-line treatment for advanced esophageal squamous cell carcinoma (ESCC) in the United States and China.
Xueqiong Cao, Hongfu Cai, Na Li, Bin Zheng, Zhiwei Zheng, Maobai Liu   +5 more
doaj   +1 more source

THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES

Фармакоэкономика, 2017
This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia, a standardized methodology to calculate QALY is in use; such an approach makes it possible to apply this universal criterion of effectiveness to the ...
N. Z. Musina, V. K. Fedyaeva
doaj   +1 more source

Retaining, and Enhancing, the QALY

Качественная клиническая практика, 2018
.
Joseph Lipscomb, Michael Drummond, Dennis Fryback, Marthe Gold, Dennis Revick, I. A. Vilum, S. L. Plavinskii, D. Yu. Belousov   +7 more
doaj  

THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS

Сибирский онкологический журнал, 2017
A new generation of aromatase inhibitors and target therapy directed at cycline-dependent kinases 4 and 6 gives a new opportunity to treat metastatic breast cancer. However, the cost of innovative therapy remains high.
S. L. Pavlinsky, P. I. Shabalkin
doaj   +1 more source

VALIDATION OF THE RUSSIAN VERSION OF A QUESTIONNAIRE FOR THE ASSESSMENT OF UTILITARIAN INDICES IN PEDIATRIC PRACTICE. STAGE II

Вопросы современной педиатрии, 2014
Aim: To create the Russian-language version of the standardized international questionnaire Health Utilities Index (HUI) applicable for children's age, on the basis of the relevant international requirements to linguistic ratification and validation of ...
I. V. Vinyarskaya, V. V. Chernikov, R. N. Terletskaya, S. V. Shcherbakova, А. N. Fetisova   +4 more
doaj   +1 more source